Targeting lineage-specific heterogeneity and hypovascular-fibrotic barriers may enable precision immunotherapy in...

Area of Science:

• Oncology
• Immunology
• Tumor Microenvironment Research

Background:

• Refractory pituitary neuroendocrine tumors (PitNETs) present significant clinical challenges due to treatment resistance.
• Therapeutic failures are linked to immune heterogeneity and a hypovascular-fibrotic barrier impeding drug delivery.

Purpose of the Study:

• To critically examine biological determinants of therapeutic resistance in the PitNET tumor microenvironment (TME).
• To propose a framework for precision immuno-oncology in managing refractory PitNETs.

Main Methods:

• Review of immune infiltration profiles and checkpoint expressions across different PitNET transcriptional lineages (PIT1, TPIT, SF1).
• Elucidation of the hypovascular-fibrotic barrier's role in limiting therapeutic penetration.
• Evaluation of advanced strategies like spatial multi-omics and focused ultrasound (FUS).

Main Results:

• Immune profiles and checkpoint expressions are lineage-specific within PitNETs.
• The hypovascular-fibrotic TME restricts drug delivery due to low vascular density and collagen deposition.
• Spatial multi-omics and FUS show promise for patient stratification and enhanced drug delivery.

Conclusions:

• A precision immuno-oncology approach, informed by TME characteristics, is crucial for treating intractable PitNETs.
• Combinatorial strategies involving vascular normalization and metabolic reprogramming may synergize with immune checkpoint inhibitors.
• This paradigm shift offers novel therapeutic avenues for refractory PitNETs.